CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Incyte Corporation

INCY
$24.91BLarge Cap

Next catalyst

Phase 2November 2026

Povorcitinib

NonSegmental Vitiligo

Get an email about INCY's next catalysts

Track Incyte (INCY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 26 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

27 upcoming, 4 past

Phase 2Next

povorcitinib Phase 2 Est. Readout

November 2026~Povorcitinib247

Estimated primary completion for povorcitinib trial (NCT05851443) in Moderate to Severe Asthma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Axatilimab Phase 2 Est. Readout (NAHL)

December 2026~Axatilimab9

Estimated primary completion for Axatilimab trial (NCT05723055) in Hodgkin Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 3

Povorcitinib Phase 3 Est. Readout (STOP-HS LTE)

December 2026~Povorcitinib617

Estimated primary completion for Povorcitinib trial (NCT06212999) in Hidradenitis Suppurativa (HS). Topline data typically follows completion by weeks to months.

Source
Phase 2

Tafasitamab Phase 2 Est. Readout

December 2026~Tafasitamab35

Estimated primary completion for Tafasitamab trial (NCT05351593) in CNS Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Ruxolitinib Phase 2 Est. Readout

January 2027~Ruxolitinib30

Estimated primary completion for Ruxolitinib trial (NCT06345495) in Splenomegaly. Topline data typically follows completion by weeks to months.

Source
Phase 2

INCA034176 Phase 2 Est. Readout

January 2027~INCA03417632

Estimated primary completion for INCA034176 trial (NCT06843408) in Chronic Graft-versus-host-disease. Topline data typically follows completion by weeks to months.

Source
Phase 2

Tafasitamab Phase 2 Est. Readout

January 2027~Tafasitamab28

Estimated primary completion for Tafasitamab trial (NCT06760156) in Large B-cell Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Retifanlimab Phase 2 Est. Readout (TRICK-MCC)

January 2027~Retifanlimab12

Estimated primary completion for Retifanlimab trial (NCT06056895) in Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8. Topline data typically follows completion by weeks to months.

Source

How INCY's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQServices-Commercial Physical & Biological Researchpharmaceuticals🇺🇸North AmericaWILMINGTON2.6K employees

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Website
Drug Pipeline

Retifanlimab

Phase 3

Metastatic Merkel Cell Carcinoma

Tafasitamab

Phase 3

Diffuse Large B Cell Lymphoma

Extracorporeal photopheresis (ECP)

Phase 3

Graft-versus-host Disease (GVHD)

Povorcitinib

Phase 3

NonSegmental Vitiligo

Topical corticosteroid

Phase 3

Atopic Dermatitis

ruxolitinib tablets

Phase 3

Polycythemia Vera

Mercaptopurine

Phase 3

Leukemia

Corticosteroids

Phase 3

Chronic Graft-versus-host-disease

Thioguanine

Phase 3

Leukemia

Bendamustine (BEN)

Phase 3

Diffuse Large B-cell Lymphoma

INCB123667

Phase 3

Ovarian Cancer

INCA034176

Phase 3

Chronic Graft-versus-host-disease

INCA33890

Phase 3

CRC (Colorectal Cancer)

INCB161734

Phase 3

Solid Tumors

Hydroxyurea (HU)

Phase 3

Polycythemia Vera

Itacitinib

Phase 3

MPN (Myeloproliferative Neoplasms)

Ruxolitinib

Phase 3

MPN (Myeloproliferative Neoplasms)

Patent 2041

pembrolizumab + epacadostat

Phase 3

Melanoma

INCA033989

Phase 3

Essential Thrombocythemia

Tacrolimus (Tac)

Phase 3

Graft-versus-host Disease (GVHD)

Epacadostat

Phase 3

Lung Cancer

Best Available Treatment

Phase 3

Essential Thrombocythemia

Ruxolitinib Cream

Phase 3

Nonsegmental Vitiligo With Genital Involvement

Baricitinib

Phase 3

Alopecia Areata

Calaspargase Pegol

Phase 3

Acute Lymphoblastic Leukemia

Ruxolitinib (Rux)

Phase 3

Graft-versus-host Disease (GVHD)

Asparaginase Erwinia chrysanthemi (recombinant)-rywn

Phase 3

Acute Lymphoblastic Leukemia

Erwinase®

Phase 3

Acute Lymphoblastic Leukemia

Nelarabine

Phase 3

Acute Lymphoblastic Leukemia

Supportive Care: Seizure prophylaxis

Phase 2

AML (Acute Myelogenous Leukemia)

Post-transplant Abatacept

Phase 2

AML (Acute Myelogenous Leukemia)

Supportive Care: Prophylaxis against infections

Phase 2

AML (Acute Myelogenous Leukemia)

All-trans retinoic acid

Phase 2

Glioma

Conditioning Regimen A

Phase 2

AML (Acute Myelogenous Leukemia)

Conditioning Regimen E

Phase 2

AML (Acute Myelogenous Leukemia)

BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Phase 2

Chronic Phase Chronic Myeloid Leukemia

Post-transplant Ruxolitinib

Phase 2

AML (Acute Myelogenous Leukemia)

Conditioning Regimen B

Phase 2

AML (Acute Myelogenous Leukemia)

PTCy (D3, D4)

Phase 2

AML (Acute Myelogenous Leukemia)

Conditioning Regimen C

Phase 2

AML (Acute Myelogenous Leukemia)

Conditioning Regimen D

Phase 2

AML (Acute Myelogenous Leukemia)

Post-transplant Tacrolimus

Phase 2

AML (Acute Myelogenous Leukemia)

Supportive Care: Growth Factors

Phase 2

AML (Acute Myelogenous Leukemia)

INCA000585

Phase 2

Immune Thrombocytopenia

INCB024360

Phase 2

Myelodysplastic Syndromes

INCMGA00012 (PD-1 antibody)

Phase 2

Pancreatic Cancer Non-resectable

Yescarta

Phase 2

Cytokine Release Syndrome

MELITAC 12.1 Peptide Vaccine

Phase 2

Mucosal Melanoma

INCAGN01876

Phase 2

Advanced Malignancies

GVAX Pancreas Vaccine

Phase 2

Metastatic Pancreatic Adenocarcinoma

INCAGN01949

Phase 2

Advanced Malignancies

R-CHOP

Phase 2

Non Hodgkins Lymphoma

Pelareorep

Phase 2

Anatomic Stage IV Breast Cancer AJCC v8

Ulixertinib

Phase 2

Myelofibrosis

Axatilimab (SNDX-6352)

Phase 2

Myelofibrosis (MF)

INCMGA00012

Phase 2

Resectable Sarcoma

SRS

Phase 2

Glioblastoma

Tuparstobart

Phase 2

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

Donor Lymphocyte Infusion (DLI)

Phase 2

Acute Myeloid Leukemia

Verzistobart

Phase 2

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8

Dovonex® calcipotriene

Phase 2

Psoriasis

Ruxolitinib Topical Cream

Phase 2

Exanthema

Pegaspargase

Phase 2

Leukemia

Vincristine Sulfate

Phase 2

Leukemia

Diprolene® AF betamethasone dipropionate cream

Phase 2

Psoriasis

Myeloablative conditioning regimen

Phase 2

Leukemia

CAPOX chemotherapy

Phase 2

Rectal Cancer

FOLFOX chemotherapy

Phase 2

Rectal Cancer

parsaclisib + ruxolitinib

Phase 2

B-Cell Malignancies

parsaclisib + ibrutinib

Phase 2

B-Cell Malignancies

Epcoritamab, tafasitamab and lenalidomide

Phase 2

Large B Cell Lymphoma

Granulocyte Colony-Stimulating Factor

Phase 2

Aplastic Anemia

JAK Inhibitor

Phase 2

Myelodysplastic/Myeloproliferative Neoplasm

topical ruxolitinib

Phase 2

Pyoderma Gangrenosum

Chimeric antigen receptor (CAR) T-cell therapy

Phase 2

Diffuse Large B Cell Lymphoma

INCB001158

Phase 2

Biliary Tract Cancer (BTC)

INCB177054

Phase 2

Solid Tumors

ICS-LABA

Phase 2

Moderate to Severe Asthma

Pemigatinib

Phase 2

Non-Small Cell Lung Cancer (NSCLC)

Patent 2040

Asparaginase Erwinia Chrysanthemi

Phase 2

Leukemia

INCB013739

Phase 2

Type 2 Diabetes

INCB000928

Phase 2

Anemia

Ruxolitinib phosphate cream

Phase 2

Psoriasis

Patent 2041

INCB054707

Phase 2

Hidradenitis Suppurativa

Parsaclisib

Phase 2

B-Cell Malignancies

Ponatinib

Phase 2

Philadelphia Positive

INCB009471

Phase 2

HIV Infections

INCB099280

Phase 2

Advanced Solid Tumor

INCAGN02385

Phase 2

Endometrial Cancer

Axatilimab

Phase 2

Chronic Graft-versus-host-disease

INCAGN02390

Phase 2

Melanoma

Best available Treatment (BAT)

Phase 2

Chronic Graft-versus-host-disease

INCB018424

Phase 2

Rheumatoid Arthritis

INCB028050

Phase 2

Rheumatoid Arthritis

Prednisone or methylprednisolone

Phase 2

Graft-versus-host Disease (GVHD)

Ruxolitinib Phosphate

Phase 2

Psoriasis

Immune effector cell therapy

Phase 2

Cytokine Release Syndrome

Platinum-based chemotherapy

Phase 2

Lung Cancer

parsaclisib + itacitinib

Phase 2

B-Cell Malignancies

MEDI4736

Phase 2

Solid Tumors

Regorafenib

Phase 2

Pancreatic Cancer

MK-3475

Phase 2

Microsatellite-instability (MSI) High Colorectal Cancer (CRC)

Post-transplant Mycophenolate mofetil

Phase 2

AML (Acute Myelogenous Leukemia)

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Incyte Corporation's drug pipeline?→

CatalystAlert tracks 103 drug candidates in Incyte Corporation's (INCY) pipeline across Phase 3, Phase 2. Its lead program is Ruxolitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Incyte Corporation's next FDA catalyst?→

Incyte Corporation's (INCY) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track INCY biotech catalysts?→

Add INCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Incyte Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply